Q3 EPS Forecast for Neurocrine Biosciences Cut by Analyst

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Investment analysts at Leerink Partnrs lowered their Q3 2025 EPS estimates for shares of Neurocrine Biosciences in a research note issued on Monday, February 17th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per share of $1.28 for the quarter, down from their previous forecast of $1.29. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share. Leerink Partnrs also issued estimates for Neurocrine Biosciences' Q4 2025 earnings at $1.27 EPS and FY2026 earnings at $6.50 EPS.

A number of other equities analysts also recently commented on NBIX. Morgan Stanley lifted their price objective on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. William Blair reaffirmed an "outperform" rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. UBS Group increased their price objective on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a "buy" rating in a research note on Thursday, January 30th. Barclays lifted their target price on Neurocrine Biosciences from $160.00 to $165.00 and gave the company an "overweight" rating in a research note on Monday, December 23rd. Finally, Wedbush dropped their price target on Neurocrine Biosciences from $157.00 to $147.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Neurocrine Biosciences presently has an average rating of "Moderate Buy" and a consensus price target of $166.90.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX traded up $4.58 during trading on Wednesday, reaching $120.69. The stock had a trading volume of 1,960,258 shares, compared to its average volume of 1,321,019. The stock has a market cap of $12.03 billion, a PE ratio of 36.68, a P/E/G ratio of 0.76 and a beta of 0.33. Neurocrine Biosciences has a one year low of $110.95 and a one year high of $157.98. The firm's 50 day moving average price is $136.75 and its two-hundred day moving average price is $129.71.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Forum Financial Management LP acquired a new position in Neurocrine Biosciences in the 4th quarter worth approximately $254,000. Peak Retirement Planning Inc. purchased a new stake in shares of Neurocrine Biosciences in the fourth quarter valued at $1,029,000. Toronto Dominion Bank grew its holdings in shares of Neurocrine Biosciences by 3.9% during the fourth quarter. Toronto Dominion Bank now owns 13,183 shares of the company's stock valued at $1,799,000 after buying an additional 499 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Neurocrine Biosciences during the fourth quarter valued at $290,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Neurocrine Biosciences by 19.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,070,096 shares of the company's stock valued at $146,068,000 after buying an additional 175,879 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Kevin Charles Gorman sold 5,844 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $116.69, for a total transaction of $681,936.36. Following the completion of the sale, the director now owns 521,618 shares in the company, valued at approximately $60,867,604.42. This represents a 1.11 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ingrid Delaet sold 1,091 shares of the stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total value of $147,285.00. Following the completion of the transaction, the insider now owns 2,507 shares of the company's stock, valued at $338,445. This trade represents a 30.32 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 236,600 shares of company stock worth $34,348,261. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.